Topic - Presenter
Welcome
Karl Mahler, Head of Investor Relations
Pharma Strategy: Sustainable growth by delivering more patient benefits at reduced cost to society
Bill Anderson, Chief Executive Officer Roche Pharmaceuticals
Commercial Opportunities: Near-term growth drivers
Teresa Graham, Head of Pharma Global Product Strategy
Late Stage Pipeline Oncology & Non-malignant Hematology
Levi Garraway, Chief Medical Officer and Head Global Product Development
Late Stage Pipeline Neuroscience & Immunology
Paulo Fontoura, Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Clinical Development
Late Stage Pipeline Ophthalmology
Nilesh Mehta, Life Cycle Leader Faricimab
Late Stage Pipeline Infectious Diseases
Barry Clinch, Global Head Infectious Diseases, Clinical Development
Appendix
Pipeline overview
Patient populations